Page 10 - Dyslipidaemia for programming

REFLECTIONS dae mia
Dyslipidaemia Global Newsletter #3 Dyslipi
Dyslipi
ADDITIONAL ARTICLES OF INTEREST aim ead

1. Evaluating the role of statins in prevention of preeclampsia: Deeper insights into maternal cardiometabolic
changes. Rao SJ, et al. J Clin Lipidol. 2022 Jul-Aug;16(4):403-416.

2. Lipoprotein(a) and its significance in cardiovascular disease: A review. Duarte Lau F, Giugliano RP. JAMA Cardiol.
2022 Jul 1;7(7):760-769.

3. Hyperlipidemia and risk for preclampsia. Poornima IG, et al. J Clin Lipidol. 2022 May-Jun;16(3):253-260.

4. Lipoprotein(a) and subclinical coronary atherosclerosis in asymptomatic individuals. Lee H, et al. Atherosclerosis.
2022 May;349:190-195.

5. Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction. Doi T, et al. J Am
Coll Cardiol. 2022 Jun 21;79(24):2383-2397.

6. Statin therapy for the primary prevention of cardiovascular disease: Pros. Razavi AC, et al. Atherosclerosis. 2022
Sep;356:41-45.

7. Statin therapy for the primary prevention of cardiovascular disease: Cons. Durai V, Redberg RF. Atherosclerosis. 2022
Sep;356:46-49.

8. Plasma lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve
stenosis during a 14-year observational period. Wodaje T, et al. Atherosclerosis. 2022 May;349:175-182.

9. Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk
populations. Liu C, et al. JAMA Cardiol. 2022 Jul 1;7(7):672-680.

10. Evaluating the use of coronary artery calcium scoring as a tool for coronary artery disease (CAD) risk stratification
and its association with coronary stenosis and cad risk factors: A single-centre, retrospective, cross-sectional
study at a tertiary centre in Pakistan. Liaquat A, et al. BMJ Open. 2022 Jul 29;12(7):e057703.

11. Effect of statin therapy on muscle symptoms: An individual participant data meta-analysis of large-scale,
randomised, double-blind trials. Cholesterol Treatment Trialists’ Collaboration. Lancet. 2022;400:832-45.

ACRONYMS:
ACEi, angiotensin-converting enzyme inhibitor; aHR, adjusted hazard ratio; ASCVD, atherosclerotic cardiovascular disease; BP,
blood pressure; CAD, coronary artery disease; CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; CVD,
cardiovascular disease; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; eGFR, estimated glomerular
filtration rate; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; ITT, intention-to-treat; LDL-C, low-density lipoprotein
cholesterol; LLT, lipid-lowering therapy; MACE, major adverse cardiovascular event; MI, myocardial infarction; OLE, open-label
extension; OR, odds ratio; PCSK9, proprotein convertase subtilisin-kexin type-9; PDC, proportion of days covered; Q2W, every 2
weeks; Q4W, every 4 weeks; REF, reference; USPSTF, US Preventive Services Task Force.

TABLE OF CONTENTS